News > Pfizer-BioNTech Covid vax shows 100% efficacy in 12-15 yrs old

Pfizer-BioNTech Covid vax shows 100% efficacy in 12-15 yrs old

Pharmaceutical companies Pfizer and BioNTech on Wednesday announced that their Covid-19 vaccine — BNT162b2 — demonstrated 100 per cent efficacy and robust antibody responses in a Phase 3 trial in adolescents between 12 to 15 years old.

Further, BNT162b2 administration was well tolerated, with side effects generally consistent with those observed in participants 16 to 25 years of age.